Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 138-144

  Konoplev, Sergej ^a   Yin, C Cameron ^a   Kornblau, Steven M ^a   Kantarjian, Hagop M ^a   Konopleva, Marina ^a   Andreeff, Michael ^a   Lu, Gary ^a   Zuo, Zhuang ^a   Luthra, Rajyalakshmi ^a   Medeiros, L Jeffrey ^a   Bueso Ramos, Carlos E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; BCR ABL1; Blast phase; Chromosome; Chronic myelogenous leukemia; NPM1; Philadelphia

Indexed keywords

ABL1 PROTEIN; B RAF KINASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; K RAS PROTEIN; NUCLEOPHOSMIN; PROTEIN; PROTEIN RET; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AKT1 GENE; AKT2 GENE; AKT3 GENE; ARTICLE; FEMALE; GENE; GENE MUTATION; GNAQ GENE; GNAS GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; NRAS GENE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PIK3CA GENE; PRIORITY JOURNAL; SCREENING;

ABNORMAL KARYOTYPE; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BLAST CRISIS; BONE MARROW; FEMALE; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PHILADELPHIA CHROMOSOME; YOUNG ADULT;

EID: 84870948020     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.701739     Document Type: Article

References (32)

1. Keung YK, Beaty M, Powell BL, et al. Philadephia chromosome positive myelodysplastic syhndrome and acute myeloid leukemiaYretrospective study and review of the literature. Leuk Res 2004; 28: 579- 586. (Pubitemid 38543195)
2. B acher U, H aferlach T, A lpermann T, et al. S ubclones with the t(9;22)/BCL-AML1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br J Haematol 2011 ; 152: 713-720.
3. Soupir CP, Vergilio J, Dal Cin P, et al. Philadelphia chromosomepositive acute myeloid leukemia. A rare aggressive leukemia with clinicopatholgical features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007 ; 127: 642-650. (Pubitemid 46587480)
4. eld CD, Lindquist LL, Brunning RD, et al. The Philadelphia chromosome in acute leukemia. Virchows Arch B Cell Pathol 1978 ; 29: 81-91. (Pubitemid 9053858)
5. C uneo A, F errant A, M ichaux JL, et al. P hiladelphia chromosomepositive acute myeloid leukemia: Cytoimmunologic and cytogenetic features. Haematologica 1996 ; 81: 423-427.
6. Swerdlow SH, Campo E, Harris NL, et al. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.
7. Vardiman JW, Th iele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classifi cation of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009 ; 114: 937-951.
8. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005 ; 106: 3733-3739. (Pubitemid 41739006)
9. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profi le, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005 ; 106: 3618-3620. (Pubitemid 41609201)
10. Falini B, Mecucci C, Tiacci E, et al. GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005 ; 352: 254-266. (Pubitemid 40110814)
11. G rossmann V, K ohlmann A, Z enger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011; 25: 557- 560.
12. Piccaluga PP, Sabattini E, Bacci F, et al. Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukemia. Leukemia 2009; 23: 1370- 1371.
13. R oche-Lestienne C, S oenen-Cornu V, G rardel-Dufl os N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002 ; 100: 1014-1018. (Pubitemid 34832631)
14. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011 ; 1185: 1208-1215.
15. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor Imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002 ; 2: 117-125. (Pubitemid 41039112)
16. W illis SG, L ange T, D emehri S, et al. H igh-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128- 2137. (Pubitemid 41291730)
17. Oyarzo MP, Lin P, Glassman A, et al. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of fl t3 gene mutations. Am J Clin Pathol 2004 ; 122: 348-358. (Pubitemid 39145539)
18. Onciu M, Schlette E, Medeiros LJ, et al. Cytogenetic fi ndings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol 2001 ; 116: 886-892. (Pubitemid 33108160)
19. Y in CC, C ortes J, G albincea J, et al. R apid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identifi ed by quantitation mutation assays. Cancer Sci 2010; 101: 2005-2010.
20. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425-3432. (Pubitemid 40627896)
21. Chen W, Jones D, Medeiros LJ, et al. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol 2005 ; 130: 726-728. (Pubitemid 43906644)
22. Patel KP, Barkoh BA, Chen Z, et al. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis. J Mol Diagn 2011 ; 13: 678-686.
23. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. C urr Protoc Hum Genet 2009; 2: 2-12.
24. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987 ; 83: 445-454.
25. Griesshammer M, Heinze B, Hellmann A, et al. Chronic myelogenous leukemia in blast crisis: Retrospective analysis of prognostic factors in 90 patients. Ann Hematol 1996 ; 73: 225-230. (Pubitemid 26401797)
26. Paietta E, Racevskis J, Bennett JM, et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: The Eastern Cooperative Oncology Group experience. Leukemia 1998; 12: 1881- 1885. (Pubitemid 28554461)
27. Berger R. Diff erences between blastic chronic myeloid leukemia and Ph-positive acute leukemia. Leuk Lymphoma 1993; 11(Suppl. 1): 235- 237. (Pubitemid 23274165)
28. G illiland DG. H ematologic malignancies. C urr Opin Hematol 2001 ; 8: 189-191. (Pubitemid 32762958)
29. P aschka P, S chlenk RF, G aidzik VI, et al. I DH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010 ; 28: 3636-3643.
30. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 2010 ; 28: 2348-2355. Roche-Lestienne C [31], Marceau A, Labis E, et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia 2011 ; 25: 1661-1664.
31. S overini S, S core J, I acobucci I, et al. I DH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia 2011 ; 25: 178-181.
32. Barton MK. Discontinuation of imatinib may be possible in chronic myelogenous leukemia. CA Cancer J Clin 2011 ; 61: 65-66.